Syncona Limited
Result of Annual General Meeting
2 August 2022
At the Annual General Meeting of Syncona Limited (the "Company") held today, all Resolutions as set out in the 'Notice of the 2022 Annual General Meeting' dated 30 June 2022 sent to shareholders of the Company (the "Notice") were duly passed.
Resolutions 1 to 12 were proposed as Ordinary Resolutions. Resolution 13 was proposed as a Special Resolution and Resolution 14 was proposed as an Extraordinary Resolution.
Details of the proxy voting results, which should be read alongside the Notice, are noted below:
|
No |
Resolution |
For |
Discretion |
Against |
Abstain (withheld) |
|
1 |
Receive and consider the Annual Audited Financial Statements of the Company for the year ended 31 March 2022, together with the Reports of the Directors and Auditors thereon |
464,372,350 (99.96%) |
(0) (0%) |
189,929 (0.04%) |
7,875 |
|
2 |
Re-appointment of Deloitte LLP (Guernsey Branch) as Auditors |
464,325,349 (99.99%) |
(0) (0%) |
53,133 (0.01%) |
191,672 |
|
3 |
Authorise the Directors to determine the remuneration of the Auditors |
464,558,338 (99.99%) |
(0) (0%) |
9,578 (0.01%) |
2,238 |
|
4 |
Re-elect Melanie Gee as a Director |
463,062,580 (99.68%) |
(0) (0%) |
1,490,199 (0.32%) |
17,375 |
|
5 |
Elect Julie Cherrington as a Director |
464,536,562 (99.99%) |
(0) (0%) |
4,217 (0.01%) |
29,375 |
|
6 |
Elect Cristina Csimma as a Director |
464,536,562 (99.99%) |
(0) (0%) |
4,217 (0.01%) |
29,375 |
|
7 |
Re-elect Virginia Holmes as a Director |
463,062,580 (99.68%) |
(0) (0%) |
1,490,199 (0.32%) |
17,375 |
|
8 |
Re-elect Rob Hutchinson as a Director |
463,029,675 (99.67%) |
(0) (0%) |
1,523,104 (0.33%) |
17,375 |
|
9 |
Re-elect Kemal Malik as a Director |
463,020,330 (99.67%) |
(0) (0%) |
1,523,104 (0.33%) |
26,720 |
|
10 |
Re-elect Gian Piero Reverberi as a Director |
463,028,580 (99.67%) |
(0) (0%) |
1,521,854 (0.33%) |
19,720 |
|
11 |
Approve the report on implementation of the Remuneration Policy for Non-Executive Directors |
463,065,971 (99.68%) |
(0) (0%) |
1,475,563 (0.32%) |
28,620 |
|
12 |
Authority to allot and issue shares |
464,193,797 (99.93%) |
(0) (0%) |
346,067 (0.07%) |
30,290 |
|
13 |
Authorise the Company to purchase its own shares |
464,346,845 (99.95%) |
(0) (0%) |
211,264 (0.05%) |
12,045 |
|
14 |
Disapply pre-emption rights |
456,459,320 (98.26%) |
(0) (0%) |
8,088,893 (1.74%) |
21,941 |
A vote withheld is not a vote in law and has not been counted in the votes for and against a resolution.
In accordance with the Listing Rule 9.6.2, a copy of all the resolutions passed other than resolutions concerning ordinary business have been submitted to the Financial Conduct Authority via the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
The full text of the resolutions can be found in the Notice, which is available on the Company's website at https://www.synconaltd.com/investors/shareholder-information/shareholder-documents/.
Enquiries
Syncona Limited
Natalie Garland-Collins / Fergus Witt
Tel: +44 (0) 7714 916615
FTI Consulting
Ben Atwell / Julia Bradshaw / Tim Stamper
Tel: +44 (0) 20 3727 1000
Copies of this press release and other corporate information can be found on the company website at: www.synconaltd.com.
About Syncona:
Syncona's purpose is to invest to extend and enhance human life. We do this by founding and building a portfolio of global leaders in life science to deliver transformational treatments to patients in areas of high unmet need.
Our strategy is to found, build and fund companies around exceptional science to create a diversified portfolio of 15-20 globally leading healthcare businesses for the benefit of all our stakeholders. We focus on developing treatments for patients by working in close partnership with world-class academic founders and management teams. Our balance sheet underpins our strategy enabling us to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
